NCT07080905: Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
- State
- Under way
- Phase
- Phase 3
- People
- 20 planned
- Started
- 28 Jul 2025
- Primary completion
- 24 Oct 2033
- Arms
- CSL222
- Results
- None posted
- 23 Jul 2025: Trial registered
- 28 Jul 2025: Trial started